Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon-α-2a vs Observation After Stopping TKI in CML
NCT02381379Phase 3Unknown
- Sponsor
- Ministry of Health Malaysia
- Start
- Mar 2015
- Primary completion
- Oct 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myeloid leukemia (CML) comparing Peginterferon-α-2a with Observation (2 arms). Primary endpoint: Relapse rate at 3 years. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02381379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381379.